AntoXa

Life-saving biodefense solutions

  • About Us
    • Management Team
  • Products
  • Investors
  • News
  • Contact
You are here: Home / Investors / The Antoxa Opportunity

The Antoxa Opportunity

March 15, 2017 By antoxa

AntoXa’s growing portfolio of medical countermeasures addresses the need for effective therapeutics to protect against biological and chemical threats and infectious disease.

  • The U.S. Strategic National Stockpile has been allocated USD$50 billion since 2001 to create a national repository of life-saving medical supplies including antitoxins.
  • AntoXa has to date secured approximately CAD$4 million towards its medical countermeasure programs and is working with the Canadian, American and Australian departments of defence to prepare for a range of chemical and biological threats.
  • Regulators give medical countermeasures a fast track to market and AntoXa is well-positioned to commercialize several products now in development.
  • AntoXa’s products address key customer concerns regarding safety, cost and shelf-life.

To learn about investment opportunities, contact:

Don Stewart, CEO
don.stewart@antoxacorp.com
416.452.7242
1920 Yonge Street, Suite 200
Toronto, Ontario, Canada,  M4S 3E2

Filed Under: Investors

Latest News

AntoXa Corporation awarded contract extension with federal government to develop plant-made protein for potential coronavirus therapy

August 17, 2021

DRDC-funded project aims to develop recombinant human ...
Read more >

AntoXa awarded federal government contract for anti-nerve agent enzyme

March 20, 2019

GUELPH, Ontario, Canada, March 20, 2019 — AntoXa Corporation has been ...
Read more >

Ashley J. Meyers appointed President and COO of AntoXa Corporation

Ashley J. Meyers appointed President and COO of AntoXa Corporation

December 20, 2018

Guelph, Ont., Canada, Dec. 20, 2018 — AntoXa Corporation announced today ...
Read more >

About Us

Plant-made biopharmaceuticals for a safer world. AntoXa Corporation is a Canadian biopharmaceutical company developing medical countermeasures to protect military and civilian personnel from biological and chemical agents that might be used in terrorist attacks, as well as outbreaks of naturally ...
Read more >

Global Demand for Biodefense Therapeutics

Governments are investing billions of dollars preparing for potential bioterrorism attacks and ...
Read more >

Subscribe to our Newsletter

vivoXPRESS® MANUFACTURING SYSTEM
The tobacco-plant-based vivoXPRESS® manufacturing platform offers several advantages over the mammalian and bacterial cell culture systems used to produce most recombinant protein pharmaceuticals. Here’s how it works.

BioPharming Info Centre

Biopharming, also known as plant molecular farming, refers to the use of genetically modified plants to produce a wide range of pharmaceuticals and industrial products. See our Biopharming Info Centre to Learn more about the science and history of using plants to produce complex therapeutic proteins.

Copyright © 2022 · AntoXa Corporation | Site by DigitalNomad.marketing and Curry Gunn & Associates